Tag archief: English Only

Daiichi Sankyo Data at ASH Showcases Scientific and Clinical Advancements Across AML/Blood Cancer Portfolio

Three oral presentations to feature analyses from global pivotal phase 3 QuANTUM-R study of quizartinib Updated phase 1 study results for valemetostat in patients with...

Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019

— Survival Data at Three Years in ZUMA-1 and Results from Study Cohort Evaluating Safety and Efficacy of Earlier Steroid Use with Yescarta® (axicabtagene ciloleucel)...

Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates

Agreement with Biogen covers Samsung Bioepis’ biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept Includes...

Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials

– Data from the Two 144-week Studies in Treatment-naïve Adults Living with HIV Presented at European AIDS Conference (EACS)– FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences,...

Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®

– Results Continue to Demonstrate Statistically Significant Advantages of Descovy® Over Truvada® for Study Measurements of Bone and Renal Safety – FOSTER CITY, Calif.–(BUSINESS WIRE)–...

Alvarez & Marsal Opens in Switzerland

The firm opens its first office in Switzerland as the next phase of its strategic growth plan and appoints four new Managing Directors ZURICH–(BUSINESS WIRE)–...

BCW Introduces BCW CyberTREE™, A Strategic Model for Cybersecurity Crisis Communications Response and Planning

NEW YORK–(BUSINESS WIRE)– BCW (Burson, Cohn & Wolfe), a leading global communications agency, today announced the launch of BCW CyberTREE™, a strategic model for cybersecurity...

Riskified Announces $165 Million Series E Funding Round Led by General Atlantic

Funding round also includes participation from Fidelity Management & Research Company, Winslow Capital Management and existing investors to support Riskified’s rapid global expansion NEW YORK–(BUSINESS...

Takeda Continues Strategic Divestitures With Sale of Select OTC and Non-Core Assets to STADA for $660 Million USD

Transaction further accelerates deleveraging Strengthens alignment of Growth & Emerging Markets Business Unit portfolio with Takeda’s global business areas OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company...

Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/ Dr. Howard Mayer, Executive Vice-President and Head of Research and Development, effective...

Proposed reclassification of Ipsen shares held by Mayroy

Mayroy files a request with the AMF for a waiver to the obligation to file a public offer PARIS–(BUSINESS WIRE)– Regulatory News: The Board of...

IFF Reports Third Quarter 2019 Results

NEW YORK–(BUSINESS WIRE)– International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF) reported financial results for the third quarter ended September 30,...

ADVA introduces multi-band GNSS receiver for 5G timing accuracy

Unique pluggable line card enables easy transition to precise ePRTC and PRTC-B based synchronization MUNICH–(BUSINESS WIRE)– ADVA (FSE: ADV) today launched the market’s first modular...

Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting

New analyses from filgotinib clinical development program reinforce the investigational medicine’s consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif....

Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute

First-in-human phase 1/2 study evaluating DS-7300, a B7-H3 targeting ADC, in patients with advanced/unresectable or metastatic solid tumors B7-H3 is a protein overexpressed in various...